ClinicalTrials.gov
ClinicalTrials.gov Menu

Cell-free Circulating DNA in Primary Cutaneous Lymphomas (MATULILA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02883517
Recruitment Status : Recruiting
First Posted : August 30, 2016
Last Update Posted : February 23, 2017
Sponsor:
Information provided by (Responsible Party):
University Hospital, Bordeaux

Brief Summary:
To evaluate the possibility of detecting cell-free circulating tumoral DNA in potentially aggressive primary cutaneous lymphomas, the investigator opted to search a representative tumor sample mutation in the blood of these patients, by digital PCR. Patients with mycosis fungoides, primary cutaneous T-cell lymphoma helper follicular phenotype and primary cutaneous diffuse large B-cell lymphoma, leg-type will be included and 4 blood samples will be collected during 12 months.

Condition or disease Intervention/treatment
Mycosis Fungoides Lymphoma, Large B-cell, Diffuse Genetic: Cytogenetic and molecular studies

Detailed Description:
Primary cutaneous lymphomas represent the second extra nodal localization of lymphomas, and are constituted by T-cell and B-cell phenotype lymphomas. Mycosis fungoides, a T-cell epidermotropic lymphoma, is the most frequent. Its clinical behavior is usually indolent but some patients have an aggressive evolution. Among B-cell cutaneous lymphomas, primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is the most aggressive. Cytogenetic and molecular studies on these tumours led to a genetic characterization of these entities. Therefore, there is not any biologic marker that can help monitoring these lymphomas. In solid tumors, mutations exhibited by the tumour tissue has been detected in plasma of patients, assessing the possibility to detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome. The concept of liquid biopsies, allowing the detection of tumour mutation in plasma has been validated in nodal diffuse large B-cell lymphoma. That's why the purpose is to evaluate the possibility to detect cell-free circulating tumoral DNA in primary cutaneous lymphomas, using a highly sensitive method (digital PCR), combined with a next generation sequencing panel of the tumour sample.

Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Detection of Somatic Mutations on Cell-free Circulating DNA in Potentially Aggressive Cutaneous Lymphomas
Actual Study Start Date : November 2016
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : September 2018


Group/Cohort Intervention/treatment
Aggressive primary cutaneous lymphomas
  • Mycosis fungoides ≥ T2b
  • Primary cutaneous T helper follicular lymphoma ≥ T2
  • Primary cutaneous diffuse large B-cell lymphoma, leg type Genetic: Cytogenetic and molecular studies Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
Genetic: Cytogenetic and molecular studies
Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.



Primary Outcome Measures :
  1. Proportion of patients who have circulating free tumor DNA (detected by Digital polymerase chain reaction) with the mutation identified on biopsy [ Time Frame: Day 1 ]
  2. Proportion of patients who have circulating free tumor DNA (detected by Digital polymerase chain reaction) with the mutation identified on biopsy [ Time Frame: Week 12 ]
  3. Proportion of patients who have circulating free tumor DNA (detected by Digital polymerase chain reaction) with the mutation identified on biopsy [ Time Frame: Week 24 ]
  4. Proportion of patients who have circulating free tumor DNA (detected by Digital polymerase chain reaction) with the mutation identified on biopsy [ Time Frame: Week 36 ]

Secondary Outcome Measures :
  1. Amount of circulating tumor DNA (number of copies / µl) [ Time Frame: Day 1 ]
  2. Amount of free circulating DNA (number of copies / µl) [ Time Frame: Day 1 ]
  3. Number of patient with presence or absence of blood lymphocyte clone identical to the tumor clone [ Time Frame: Day 1 ]
  4. Number of patient with presence or absence of blood lymphocyte clone identical to the tumor clone [ Time Frame: Week 12 ]
  5. Number of patient with presence or absence of blood lymphocyte clone identical to the tumor clone [ Time Frame: Week 24 ]
  6. Number of patient with presence or absence of blood lymphocyte clone identical to the tumor clone [ Time Frame: Week 36 ]
  7. Number of patient with presence or absence of mutation identified in circulating blood [ Time Frame: Day 1 ]
  8. Number of patient with presence or absence of mutation identified in circulating blood [ Time Frame: Week 12 ]
  9. Number of patient with presence or absence of mutation identified in circulating blood [ Time Frame: Week 24 ]
  10. Number of patient with presence or absence of mutation identified in circulating blood [ Time Frame: Week 36 ]

Biospecimen Retention:   Samples With DNA

a collection of plasma collected at different times during the management of patients with aggressive cutaneous lymphomas followed at the University Hospital of Bordeaux.

Collection of tumor tissue biopsies for Next Generation Sequencing analysis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patient with an aggressive cutaneous Lymphomas
Criteria

Inclusion Criteria:

  • age > 18 years;
  • French social security system affiliation or equivalent;
  • Patient with an aggressive cutaneous lymphoma (PCDLBCL-LT, mycosis fungoides, T helper follicular cutaneous lymphoma) diagnosed and monitored at the university hospital of Bordeaux;
  • Written and informed consent obtained for genetic blood test;
  • Biopsy sample available for molecular analysis.

Exclusion Criteria:

  • Another cancer (except "in situ" and surgery treated cutaneous carcinomas) in the precedent 5 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02883517


Contacts
Contact: Anne PHAM-LEDARD, MD +335 56 79 47 05 anne.pham-ledard@chu-bordeaux.fr
Contact: Christine ALFARO +335 56 79 49 52 christine.alfaro@chu-bordeaux.fr

Locations
France
University Hospital of Bordeaux - Hospital Saint André Recruiting
Bordeaux, France, 33000
Contact: Anne PHAM-LEDARD, MD    +335 56 79 49 52    anne.pham-ledard@chu-bordeaux.fr   
Contact: Christine ALFARO    +335 56 79 49 52    christine.alfaro@chu-bordeaux.fr   
Principal Investigator: Anne PHAM-LEDARD, MD         
Sponsors and Collaborators
University Hospital, Bordeaux
Investigators
Principal Investigator: Anne PHAM-LEDARD, MD University Hospital, Bordeaux

Responsible Party: University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT02883517     History of Changes
Other Study ID Numbers: CHUBX2015/35
First Posted: August 30, 2016    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by University Hospital, Bordeaux:
cell-free circulating DNA;
digital PCR
liquid biopsy

Additional relevant MeSH terms:
Mycoses
Mycosis Fungoides
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell